Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03492229 · ClinicalTrials.gov registry record · NA

Cortical Priming to Optimize Gait Rehabilitation Post Stroke

A NA study of Stroke, sponsored by University of Illinois at Chicago.

Completed
Registry status
NA
Development phase
81
Enrollment target
1
Study location

NCT03492229 is a NA study of Stroke that has completed, run by University of Illinois at Chicago. The registered enrollment target is 81 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03492229, a NA study of Stroke, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
NA
Development phase
81 participants
Enrollment target
1
Study location

Study Summary

Over four million stroke survivors currently living in the United States are unable to walk independently in the community. To increase the effectiveness of gait rehabilitation, it is critical to develop therapies that are based on an understanding of brain adaptations that occur after stroke. This project will be the first step towards the development of a novel therapeutic approach using brain stimulation to increase walking capacity in stroke survivors and understand the neural mechanisms that are associated with impairment and functional recovery.

Conditions Studied

Interventions

  • OTHER tDCS
  • OTHER AMT
  • BEHAVIORAL Treadmill training

Study Locations (1)

Illinois

  • The University of Illinois at Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2014-01-01
Est. Completion 2020-08-15
Phase NA

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT03492229

The ClinicalTrials.gov registry entry for NCT03492229 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which tDCS is the first listed.

NCT03492229 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT03492229 about?

NCT03492229 is a clinical study titled "Cortical Priming to Optimize Gait Rehabilitation Post Stroke". Over four million stroke survivors currently living in the United States are unable to walk independently in the community. To increase the effectiveness of gait rehabilitation, it is critical to develop therapies that are based on an understanding of brain adaptations that occur after stroke. This ...

What is the current status of trial NCT03492229?

This trial is currently completed. It is a NA study. The enrollment target is 81 participants. The study started on 2014-01-01. Estimated completion is 2020-08-15.

What conditions does trial NCT03492229 study?

This clinical trial studies the following conditions: Stroke.

What interventions are being tested in trial NCT03492229?

The interventions under investigation include: tDCS (OTHER), AMT (OTHER), Treadmill training (BEHAVIORAL).

Who is sponsoring clinical trial NCT03492229?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03492229 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.